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Background: The association between low serum testosterone levels, visceral adipose tissue (VAT), and metabolic
syndrome is now well known. However, the relationship between hepatic steatosis and serum testosterone levels
has not been extensively studied. Our aim was to investigate the association of serum total testosterone levels with
nonalcoholic fatty liver disease (NAFLD), adjusting for the influence of VAT and insulin resistance.
Methods: This study is a retrospective observational cross-sectional one of healthy Korean men and was conducted
at the Seoul National University Hospital Healthcare System Gangnam Center. We used data obtained from 495
men who were at least 20 years of age and who had undergone blood testing, abdominal computed tomography,
and ultrasonography. Multiple logistic regression analysis was used to explore the association of serum total
testosterone levels with NAFLD.
Results: Men in the low serum testosterone quintile were at a higher risk for NAFLD than men in the highest
serum testosterone quintile. After adjusting for age, smoking, diabetes, exercise, BMI, triglycerides, and high-density-
lipoprotein cholesterol, subjects with serum testosterone levels in the lowest quintile had an odds ratio (OR) (95%
confidence interval (CI)) of 5.12 (2.43–10.77) for NAFLD (p value, 0.0004). The inverse association between serum
testosterone and NAFLD was attenuated by further adjustment for variables including VAT; however, it remained
statistically significant (OR (95% CI): 4.52 (2.09–9.80) in the lowest quintile; p value=0.004).
Conclusions: A low serum total testosterone level was independently associated with NAFLD. This report is the first
one suggesting the association remains unchanged even after controlling for VAT and insulin resistance.
Keywords: Nonalcoholic fatty liver disease, Total testosterone, Visceral adipose tissueBackground
Nonalcoholic fatty liver disease (NAFLD) is one of the
most common causes of chronic liver disease in South
Korea [1] as well as in North America and Europe,
where the prevalence of NAFLD is reported to be up to
30% in the general population [2,3]. NAFLD has been
found to be closely related to abdominal obesity, dyslipi-
demia, type 2 diabetes, and metabolic syndrome, all of
which are risk factors for cardiovascular disease (CVD)* Correspondence: hyuktae@gmail.com
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reproduction in any medium, provided the or[4-6]. Furthermore, several recently published prospect-
ive studies have shown that NAFLD is an independent
risk factor for CVD [7-11]. Insulin resistance is regarded
as the major factor contributing to the pathogenesis of
NAFLD [12]; moreover, NAFLD has been reported to be
a very early and sensitive indicator of insulin resistance
[13,14]. Similarly, increased visceral adipose tissue
(VAT), which induces insulin resistance and plays a key
role in the development of metabolic syndrome, has
been well established as a major risk factor for NAFLD
[15,16].
Numerous studies have shown that low serum testos-
terone levels in men are associated with an increased
risk of obesity, abdominal obesity, and metabolic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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serum testosterone levels and metabolic syndrome is
often explained by VAT accumulation and insulin resist-
ance [19,21-23]. Testosterone exerts contrasting influ-
ences on muscle and VAT by affecting the commitment
of pluripotent stem cells and by suppressing the growth
of preadipocytes [19]. Based on the inverse correlation
of VAT, metabolic syndrome, and insulin resistance to
serum testosterone levels [19,21-23], one expects a simi-
lar relation between hepatic steatosis and serum testos-
terone levels; however, this potential relationship has not
been extensively investigated. In an early study, 10
patients with hepatic steatosis were reported to have
lower serum testosterone levels than reference subjects
of the same age [24]. A German study found that men
with low serum testosterone levels were at a higher risk
of hepatic steatosis than men with high serum testoster-
one levels [25]. Recently, a study that investigated a co-
hort of 117 men showed that raising serum testosterone
concentrations to normal levels by treatment with paren-
teral testosterone for 1 year improved the levels of alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST), as well as weight, body mass index (BMI), waist
size, and lipid profiles [26]. Low serum testosterone levels
are thus closely related with VATaccumulation and insulin
resistance [17,22], both of which are known to play im-
portant roles in the pathogenesis and prognosis of NAFLD
[15]. We hypothesized that the testosterone level would be
associated with NAFLD and that VAT might have a con-
founding effect on their association. In the present study,
our aim was to investigate the association of serum total
testosterone levels with NAFLD after adjusting for the in-
fluence of VAT and insulin resistance.
Methods
Participants and study design
This study is a retrospective observational cross-
sectional one of healthy Korean men who were aged
20 years or more and who voluntarily visited the Seoul
National University Hospital Healthcare System Gang-
nam Center between January 2008 and April 2010 for
routine health checkups. Study data were obtained using
questionnaires, anthropometric measurements, blood
samples, abdominal computed tomography (CT), and
ultrasonography. Among 28,670 examinees, those with
missing data on key variables (1,298 examinees who had
not undergone abdominal ultrasonography; 21,425, ab-
dominal CT scans; 4890, serum total testosterone deter-
mination) were excluded from the study. We included
only the remaining 1057 men who underwent an exam-
ination of serum total testosterone, abdominal ultrason-
ography, and abdominal CT scans of their own accord,
which was necessarily a convenience sample. All exami-
nees routinely took serology tests for hepatitis B surfaceantigen (HBsAg) and hepatitis C antibody (anti-HCV).
Of the remaining 1057 men, 77 subjects were excluded
on the grounds of HBsAg or anti-HCV positivity. By
using self-report questionnaires, we also excluded 433
men who consumed more than 140 g of alcohol per
week, had a medical history of other types of hepatitis
such as autoimmune hepatitis and chronic viral liver dis-
ease, cholestasis, and other metabolic liver diseases, or
had previously used steatogenic medications including
antiretroviral drugs, antiarrhythmic drugs, anticancer
drugs, corticosteroids and hormone.
In addition, 52 subjects were excluded because of
missing data on key variables such as smoking, medical
history of diabetes, and physical activity. The final ana-
lysis included 495 men. Among the participants
included, there were no subjects who had the evidence
of hepatic cirrhosis or portal hypertension (such as
splenomegaly and esophageal varix) on ultrasonography,
abdominal CT or gastroscopy. This study protocol was




The diagnosis of NAFLD was based on abdominal ultra-
sonography (Acuson, Sequoia 512; Siemens, Mountain
View, CA) performed by experienced radiologists
blinded to the medical information and the laboratory
parameters of the participants. Fatty infiltration of the
liver was diagnosed if hepatorenal contrast and liver
brightness were detected [27]. The subjects thus identi-
fied as having a fatty liver in the absence of other poten-
tial causes of hepatitis such as excessive alcohol
consumption (>140 g/week) were diagnosed with
NAFLD [28,29].
Serum total testosterone
Blood samples for the measurement of serum total tes-
tosterone were collected via venipuncture performed be-
tween 8:00 and 11:00 AM. Serum total testosterone was
measured using the Coat-A-Count total testosterone kit
(Siemens Diagnostics Inc., Los Angeles, CA, USA). The
Coat-A-Count procedure is a solid-phase radioimmuno-
assay that uses a testosterone-specific antibody-coated
polypropylene tube and reports results within the range
of 0.04–16 ng/mL.
Other clinical and laboratory assessments
Medical history and life style, including information on
liver disease, diabetes, smoking, alcohol consumption,
and exercise, were documented using self-report ques-
tionnaires. We surveyed the average frequency and
amount of alcohol consumption per week. Anthropo-
metric data were measured by trained personnel, who
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and body weight were measured using a digital scale,
and BMI (kg/m2) was calculated. Waist circumference
(WC) was measured at the midpoint between the lower
costal margin and the iliac crest [30]. Laboratory exami-
nations included determination of AST, ALT, gamma-
glutamyl transpeptidase (γ-GT), alkaline phosphatase
(ALP), total bilirubin, fasting glucose, fasting insulin, gly-
cosylated hemoglobin (HbA1c), high-sensitivity C-
reactive protein (hs-CRP), total cholesterol, and trigly-
ceride (TG) levels. Venous blood samples were taken
from all examinees between 8:00 and 11:00 AM after a
minimum 14-h overnight fast. All biochemical determi-
nations were conducted in the same laboratory with
standard methods. Homeostasis model assessment of in-
sulin resistance (HOMA-IR) was used as an indicator of
insulin resistance and was defined as follows: fasting in-
sulin (μIU/mL) × fasting plasma glucose (mmol/L)/22.5
[31]. Data on adipose tissue area were acquired through
use of the CT cross-sectional scan, a validated procedure
that has been demonstrated to show very low interobser-
ver variation [32,33]. The subjects underwent abdominal
CT with a 16-detector row CT scanner (Somatom Sen-
sation 16; Siemens Medical Solutions, Forchheim, Ger-
many) in the supine position. A 5-mm-thick slice
obtained at the level of the umbilicus with a 0.5-s scan
time was used to calculate abdominal fat compartments
by means of CT (Rapidia 2.8; INFINITT, Seoul, Korea).
VAT was defined as intraperitoneal fat bounded by the
parietal peritoneum or transversalis fascia, excluding the
vertebral column and paraspinal muscles, organs, blood
vessels, and bowels.
Statistical analysis
The general characteristics of the participants grouped
according to the presence of NAFLD were compared
using the Student’s t-test, the two-sample Wilcoxon
rank-sum test, and Pearson’s Chi-squared test. We con-
structed 3 models and used the multiple logistic regres-
sion to explore the association of serum total
testosterone with NAFLD, after adjusting for variables
such as age, diabetes, smoking, exercise, BMI, VAT,
HOMA-IR, and hs-CRP. The statistical significance of
the nonlinear effects of independent variables was tested
by the likelihood ratio test in the logistic regression
models. Multicollinearity was assessed using the variance
inflation factors (VIFs) [34]. A large proportion of our
study subjects had normal serum total testosterone
levels over 3 ng/mL. Therefore, we additionally analyzed
the association between NAFLD and serum total testos-
terone in the subgroup of 413 subjects with normal
serum total testosterone levels [35]. The statistical ana-
lyses were performed using STATA, version 10.0. and R
version 2.12.2 (The R Foundation for StatisticalComputing, Vienna, Austria). Statistical significance was
defined by a two-tailed p-value of <0.05.
Results
General characteristics of the study subjects
NAFLD was found in 251 subjects (50.71%). Men with
NAFLD showed lower testosterone levels (3.94 ng/mL
vs. 4.83 ng/mL) and more unfavorable metabolic profiles.
The mean VAT in the NAFLD group was significantly
higher than that in the non-NAFLD group (164.79 cm2
vs. 106.74 cm2). The NAFLD group had higher propor-
tions of diabetics (27.09% vs. 12.30%), and elevated FBS
levels (101 mg/dL vs. 96 mg/dL). The NAFLD group also
showed significantly higher hs-CRP (0.09 mg/dL vs.
0.04 mg/dL) and HOMA-IR (2.67 mg/dL vs 1.76 mg/dL)
than the non-NAFLD group. Further characteristics of
study subjects with and without NAFLD are presented
in Table 1.
NAFLD and serum testosterone levels
In both high- (VAT ≥ 100 cm2) and low- (VAT< 100
cm2) VAT groups, the mean age-adjusted prevalence of
NAFLD decreased as the serum testosterone level
increased from the 1st quintile to the 5th quintile (Fig-
ure 1). The association between serum total testosterone
levels and NAFLD was examined by employing multiple
logistic regression analysis with potential confounding
variables such as age, smoking, diabetes, exercise, BMI,
TGs, HDL-C, HOMA-IR, hs-CRP, and VAT controlled.
An inverse relationship between serum total testosterone
levels and NAFLD was shown in all models (p value:
0.0004 in model 1, 0.0006 in model 2, and 0.004 in
model 3) (Table 2). As the serum testosterone level
decreased from the 5th quintile to the 1st quintile, the
adjusted odds ratio (OR) for NAFLD increased. The OR
and 95% CI values in the 1st quintile were 5.12 (CI,
2.43–10.77) in model 1, 4.99 (2.36–10.57) in model 2,
and 4.52 (2.09–9.80) in model 3. A linear trend was seen
in all models (p value for the trend < 0.001 for all mod-
els). Although the association was slightly attenuated in
models 2 and 3 compared to those in model 1, the stat-
istical significance of the association between serum
total testosterone level and NAFLD persisted. The cor-
relation coefficients between VAT and BMI, TGs, HDL-
C, HOMA-IR, and hs-CRP were 0.653, 0.300, -0.312,
0.205, and 0.147, respectively. However, the VIFs for in-
dependent variables in all models in Table 2 were lower
than 2.1. Therefore, no evidence of a serious multicolli-
nearity effect was present. Similar results were observed
in the subgroup analysis conducted with 413 subjects
who had normal serum testosterone levels (≥3 ng/mL).
An inverse association between serum total testosterone
levels and NAFLD was also shown in all models (p value:
0.0036 in model 1, 0.0044 in model 2, and 0.0292 in
Table 1 General characteristics of study subjects categorized by the presence of NAFLD
no NAFLD (n = 244) NAFLD (n= 251) p value
Age * 54.98 (10.22) 53.85 (9.83) 0.2118
Total testosterone (ng/mL) 4.83 (3.73–5.96) 3.94 (3.10–4.85) < 0.0001
Smoking † 0.310
non-smoker 72 (29.51) 59 (23.51)
ex-smoker 110 (45.08) 125 (49.8)
current smoker 62 (25.41) 67 (26.69)
drinking amount (g/week) 21.04 (0–71.01) 8.53 (0–59.7) 0.0595
Exercise † 0.013
yes 193 (79.1) 174 (69.32)
WC (cm) 85 (81–89.9) 91.5 (88–95.5) < 0.0001
BMI (kg/m2) 23.56 (22.13–25.10) 26.14 (24.38–27.78) < 0.0001
VAT (cm2) 106.74 (80.62–142.86) 164.79 (135.97–197.95) < 0.0001
Diabetes † < 0.001
yes 30 (12.30) 68 (27.09)
FBS (mg/dL) 96 (90–103) 101 (93–114) < 0.0001
SBP (mmHg) * 118.97 (13.02) 122.44 (13.86) 0.0043
DBP (mmHg) * 79.15 (9.81) 80.83 (10.94) 0.0734
total cholesterol (mg/dL) * 196.27 (34.46) 199.79 (37.10) 0.2747
TGs (mg/dL) 95 (71–130) 140 (99–195) < 0.0001
HDL-C (mg/dL) 51 (44–59) 44 (40–51) < 0.0001
LDL-C (mg/dL) * 125.51 (33.43) 130.18 (33.26) 0.1198
Total bilirubin (mg/dL) 1.1 (0.85–1.3) 1.1 (0.9–1.3) 0.687
ALP (IU/L) 59 (49.5–69) 62 (52–72) 0.018
AST (IU/L) 22 (19–27) 26 (22–33) < 0.0001
ALT (IU/L) 22 (17–30) 33 (24–49) < 0.0001
γ-GT (IU/L) 27 (20–39) 34 (26–49) < 0.0001
hs-CRP (mg/dL) 0.04 (0.04–0.15) 0.09 (0.03–0.2) 0.0001
HOMA-IR (mg/dL) 1.76 (1.33–2.29) 2.67 (1.96–3.48) 0.0001
Metabolic syndrome † < 0.001
yes 41 (16.80) 130 (51.79)
a Data for continuous variables without a normal distribution are presented as the median (range, Quartile 25–Q75) and were tested by the two-sample Wilcoxon
rank-sum test.
b Data for continuous variables with a normal distribution are shown as the mean (± standard deviation) and were tested by the Student’s t-test.
c In the case of categorized variables, the number (n) and proportion (%) of subjects were tested by the Pearson’s Chi-square test.
* Mean (± standard deviation).
† the number (n) and proportion (%) of subjects.
WC, waist circumference; BMI, body mass index; VAT, visceral adipose tissue; FBS, fasting blood sugar; SBP, systolic blood pressure; DBP, diastolic blood pressure;
TGs, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ALP, alkaline phosphatase; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; γ-GT, gamma-glutamyl transpeptidase; hs-CRP, high-sensitivity C-reactive protein; HOMA-IR, homeostasis model
assessment of insulin resistance.
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the trend: 0.001 in model 1 and model 2; 0.004 in model
3) Additional file 1: Table S1.
Discussion
In this study, we found that low levels of serum total tes-
tosterone was independently associated with NAFLD
among apparently healthy Korean men. This inverse as-
sociation between serum testosterone and NAFLDpersisted even after controlling for the effect of VAT, in-
sulin resistance (as HOMA-IR), and low-grade inflam-
mation (as hs-CRP), which are considered as possible
links between testosterone and NAFLD.
Few studies have investigated the association be-
tween testosterone and fatty liver, and even fewer
have addressed the potential relation between testos-
terone and NAFLD. A case–control study on men
with chronic alcoholism suggested no association
1st 2nd 3rd 4th 5th

































Figure 1 Age-adjusted prevalence of non-alcoholic fatty liver disease by serum testosterone levels (stratified by VAT) a the range of
serum testosterone quintiles (ng/mL): 1st quintile (0.11–3.17), 2nd quintile (3.18–3.88), 3rd quintile (3.92–4.78), 4th quintile (4.8–5.7),
and 5th quintile (5.71–13.43) VAT, visceral adipose tissue.
Kim et al. BMC Gastroenterology 2012, 12:69 Page 5 of 8
http://www.biomedcentral.com/1471-230X/12/69between serum testosterone and fatty liver [36], but
this study included only 20 cases and 20 age-matched
controls, with the study population consisting of
chronic alcoholics. By contrast, a recent large observa-
tional study on 1912 German men showed an inverse
association between hepatic steatosis and serum tes-
tosterone levels [25], a finding consistent with that in
our study.
The mechanisms underlying the association between
testosterone and NAFLD are still largely unclear. One
possible explanation is the accumulation of VAT and
subsequent insulin resistance among men with low
serum testosterone. Men with testosterone levels in the
lower range are well known to have an increased risk of
VAT accumulation, which in turn is related to higher in-
sulin resistance [17,22,37]. Excess VAT results in expos-
ure of the liver to higher amounts of free fatty acids,
which lead to hepatic insulin resistance and ultimately
to systemic insulin resistance [38], and which are
involved in the pathogenesis and prognosis of NAFLD
[15,16]. There is also evidence that testosterone directlyimproves insulin sensitivity [39]. Research conducted at
the Massachusetts General Hospital concluded that
impaired Leydig cell function is directly associated with
insulin resistance in men [39]. These findings led to the
assumption that the association between low serum total
testosterone levels and NAFLD might be mediated by
the effect of VAT and insulin resistance. In the same
context, the attenuation of the association between
serum testosterone and NAFLD after adjusting for VAT
and HOMA-IR suggests that VAT and insulin resistance
may partially influence the pathway between testoster-
one and NAFLD.
Low-grade inflammation could be another possible
link between testosterone and NAFLD. The chronic in-
flammatory state is fundamental to the progression of
NAFLD [40,41]. Low serum testosterone is associated
with markers of inflammation [42-44], and testosterone
replacement therapy in men has been observed to have
an anti-inflammatory effect, with a reduction in TNF-α,
IL-1b, and sIL-6r levels and an increase in IL-10 and hs-
CRP levels [1,26,42,45,46].
Table 2 The association between NAFLD and serum testosterone levels in the 495 subjects included in the study
Model 1* Model 2† Model 3{
Total testosterone (ng/mL) OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
1st quintile (0.11–3.17), 5.12 (2.43–10.77) 0.0004 4.99 (2.36–10.57) 0.0006 4.52 (2.09–9.80) 0.0040
2nd quintile (3.18–3.88) 2.62 (1.28–5.38) 2.48 (1.20–5.12) 2.31 (1.09–4.88)
3rd quintile (3.92–4.78) 3.39 (1.68–6.84) 3.33 (1.65–6.75) 2.72 (1.31–5.65)
4th quintile (4.80–5.70) 2.30 (1.12–4.70) 2.22 (1.09–4.57) 2.01 (0.96–4.23)
5th quintile (5.71–13.43) 1 1 1
p for the trend < 0.001 < 0.001 < 0.001
a Multiple logistic regression was used to analyze the associations between NAFLD and serum total testosterone levels.
b p value: tested by the Wald test.
* Model 1: adjusted for age, smoking, diabetes, exercise, BMI, TGs, and HDL-C.
† Model 2: Model 1 +HOMA-IR and hs-CRP.
{ Model 3: Model 2 + VAT (as the continuous variable).
OR, odds ratio; CI, confidence interval.
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NAs) in the liver or the activity of hepatic lipase
[6,44,47]. Recent studies provide evidence that miRNAs
are abundant in the liver and modulate a diverse
spectrum of liver functions [6]. Moreover, deregulation
of miRNA expression may be a key pathogenetic factor
in many liver diseases [6]. Testosterone has been
reported to potentially regulate miRNAs in the mouse
liver [44], but the molecular mechanisms underlying
transcriptional regulation of miRNA genes in the liver
remain largely unknown [6]. A study reported that the
activity of hormone-sensitive lipase is affected by testos-
terone in the adipose tissue and heart of the male rat
[47]. These observations have only been reported in ani-
mals; hence, we could not establish definite conclusions.
Further studies are necessary to uncover new mechan-
isms linking testosterone and NAFLD.
Our study had some limitations. First, we used ultra-
sonography, which cannot identify fatty infiltration
below 30%, as the mode of diagnosis. While liver biopsy
is regarded as the gold standard for detecting hepatic
steatosis [2], liver biopsy was not feasible in the case of
this population-based study. Ultrasonography is the
diagnostic test of choice for NAFLD, because it is nonin-
vasive, safe, sensitive (up to 93%), and specific (up to
89%) in terms of identifying fatty infiltration [48]. Its
clinical efficacy in this regard has also been proven, since
a recent study on Koreans showed that ultrasonography-
diagnosed NAFLD acts as an independent risk factor for
coronary heart disease [11]. Second, although we
checked the medical history of liver disease and previous
use of steatogenic drugs through the self-report ques-
tionnaires, it was possible that rare liver diseases such as
autoimmune hepatitis and Wilson’s disease and fatty
liver disease caused by steatogenic drugs were not com-
pletely excluded considering the recall bias of self-report
questionnaires. Third, only serum total testosterone was
used to assess testosterone levels because of the absenceof available data on free testosterone and sex-hormone
binding globulin (SHBG). Fourth, the use of a conveni-
ence sample and a cross-sectional design limited the
drawing of conclusions on causality. Fifth, the findings
are restricted by sex because only men were used in this
study. Since testosterone plays a role in energy metabol-
ism in females as well, the role of this hormone in fe-
male NAFLD will also need to be examined. Despite
these limitations, the contribution of this study is that it
is the first one to identify the association of testosterone
with NAFLD after adjusting for the effect of VAT and in-
sulin resistance. Further longitudinal cohort studies are
needed to verify the causal relationship between NAFLD
and total serum testosterone levels, and well-designed
randomized clinical trials could show whether testoster-
one replacement therapy can improve NAFLD.
Conclusions
In conclusion this study shows that low levels of serum
total testosterone was independently associated with
NAFLD. This inverse association was independent of the
effect of VAT, insulin resistance (as HOMA-IR), and
low-grade inflammation (as hs-CRP).
Additional file
Additional file 1: Table S1. The association between NAFLD and
serum total testosterone levels (in the subgroup of 413 subjects with
total testosterone ≥ 3.0 ng/mL).
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